cbdMD Inc. surges 32.17% amid strong market context
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 17 Dec 25
Source: Coinmarketcap
cbdMD Inc. shares surged by 32.17% in pre-market trading, reaching a 20-day high. This significant price movement comes amid broader market strength, with the Nasdaq-100 up 0.36% and the S&P 500 up 0.29%.
The surge in cbdMD's stock price is attributed to a notable increase in investor interest following compliance news, which has positively impacted the company's market perception. This aligns with the broader trend in the market, where stocks are generally performing well, contributing to the positive sentiment surrounding cbdMD.
As cbdMD continues to gain traction, the implications for the company could be substantial, potentially leading to increased investor confidence and further stock price appreciation in the near future.
Analyst Views on YCBD
Wall Street analysts forecast YCBD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for YCBD is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.754
Low
2.00
Averages
2.00
High
2.00
Current: 0.754
Low
2.00
Averages
2.00
High
2.00
About YCBD
cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
